MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 7, 2013, Pages 1105-1115

  Zhang, Liuping ^a   Tang, Hua ^a   Kou, Yao ^a   Li, Rui ^a   Zheng, Yueyong ^a   Wang, Qiang ^a   Zhou, Xiaoyu ^a   Jin, Liangbin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer cachexia; Inflammation; MG132; NF B; Ubiquitin proteasome pathway

Indexed keywords

ALBUMIN; ATROGIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLUCOSE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; SYNAPTOTAGMIN I; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; CACHEXIA; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; FOOD INTAKE; GASTROCNEMIUS MUSCLE; MALE; MOLECULAR MECHANICS; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TUMOR GROWTH; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CACHEXIA; CARBOHYDRATE METABOLISM; CELL LINE, TUMOR; INTERLEUKIN-6; LEUPEPTINS; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROTEASOME INHIBITORS; PROTEOLYSIS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION; WEIGHT LOSS;

EID: 84879233836     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1412-6     Document Type: Article

References (41)

1. Adams V et al (2008) Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol 384(1):48-59
2. Agustsson T et al (2007) Mechanism of increased lipolysis in cancer cachexia. Cancer Res 67(11):5531-5537 (Pubitemid 46997295)
3. Ahmed AS et al (2010) Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132. Arthritis Rheum 62(7):2160-2169
4. Argiles JM, Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19(3):223-248 (Pubitemid 29198276)
5. Bodine SC et al (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294(5547):1704-1708 (Pubitemid 33104839)
6. Cai D et al (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119(2):285-298 (Pubitemid 39360909)
7. Cao PR, Kim HJ, Lecker SH (2005) Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37(10):2088-2097 (Pubitemid 41206823)
8. Caron AZ et al (2011) The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC musculoskeletal disord 12:185
9. Carson JA, Baltgalvis KA (2010) Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38(4):168-176
10. Dodson S et al (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265-279
11. Faber J et al (2008) Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia. Br J Cancer 99(12):2029-2036
12. Fearon KC (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44(8):1124-1132
13. Fearon K et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489-495
14. Glass DJ (2010) Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 13(3):225-229
15. Gomes MD et al (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98(25):14440-14445 (Pubitemid 33121410)
16. Guo N, Z. Peng (2012) MG132 a proteasome inhibitor, induces apoptosis in tumor cells. Asia-Pacific j clin oncol
17. Guttridge DC et al (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289(5488):2363-2366
18. Holroyde CP et al (1984) Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 44(12 Pt 1):5910-5913 (Pubitemid 15183610)
19. Inoue S et al (2009) The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 156(1):172-182
20. Jamart C et al (2011) Prevention of muscle disuse atrophy by MG132 proteasome inhibitor. Muscle Nerve 43(5):708-716
21. Jing H et al (2012) MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFkappaB pathways. J surg res 176(1):63-73
22. Judge AR et al (2007) Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol 292(1):C372-C382 (Pubitemid 46115145)
23. Kawamura I et al (1999) Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6(1):91-97 (Pubitemid 29043698)
24. Kumar A et al (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82(7):434-448 (Pubitemid 39044283)
25. Li H, Malhotra S, Kumar A (2008) Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med 86(10):1113-1126
26. Lombardo T et al (2012) Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukemic cells U937 and the induction of low levels of intracellular superoxide anion. Toxicol Appl Pharmacol 258(3):351-366
27. Ma Y et al (2011) MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-kappaB/TGFbeta1 pathway. Biochem Pharmacol 81(10):1228-1236
28. Melstrom LG et al (2007) Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22(7):805-814 (Pubitemid 47034146)
29. O'Leary EM, Igdoura SA (2012) The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. Mol Genet Metab 107(1-2):173-185
30. Pajak B et al (2008) Crossroads of cytokine signaling-the chase to stop muscle cachexia: an official. J physiol pharmacol 59(Suppl 9):251-264
31. Saini A, Al-Shanti N, Stewart CE (2006) Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17(6):475-486 (Pubitemid 44793120)
32. Schneider M et al (2012) Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol 86(18):10112-10122
33. Sung ES et al (2012) The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res 318(13):1564-1576
34. Tanaka Y et al (1990) Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50(8):2290-2295 (Pubitemid 20134483)
35. Thaloor D et al (1999) Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. American j physiol 277(2 Pt 1):C320-C329
36. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89(2):381-410
37. Wang H et al (2011a) Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Lett 305(1):40-49
38. Wang Y et al (2011b) Comparative study of the influence of proteasome inhibitor MG132 and ganciclovir on the cytomegalovirus-specific CD8(+) T-cell immune response. Viral Immunol 24(6):455-461
39. Winder SJ et al. (2011) The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish. PLoS currents, 3: p. RRN1286
40. Zanotto-Filho A et al (2012) Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3 K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK 1/2 signaling. Invest New Drugs 30(6):2252-2262
41. Zhou X et al (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142(4):531-543